Hagop Kantarjian: Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
Hagop Kantarjian, Associate Vice President for Global Academic Programs at MD Anderson Cancer Center, shared on X a recent paper published in Leukemia Journal:
“New in Leukemia Journal: Outcomes in intensively treated KMT2Ar AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors.”
Title: Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
Authors: Alex Bataller, Hannah E. Goulart, Ghayas C. Issa, Courtney D. DiNardo, Naval Daver, Tapan Kadia, Alexandre Bazinet, Ian M. Bouligny, Jayastu Senapati, Fadi G. Haddad, Gautam Borthakur, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Guillermo Montalban-Bravo, Guiling Tang, Sanam Loghavi, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian and Elias Jabbour.
Read more about the article.
Find more posts on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023